|
|
|
| 
|
|
|
My Recent Searches
|
|
|
|
|
|
|
|
|
Concert Pharmaceuticals, Inc. (CNCE) |
|
|
$8.37 0.00 (0.00%) as of 4:30 Fri 3/3
|
|
Download |
|
|
| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
47,940,000 |
| Market
Cap: |
401.26(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$8.37 - $8.37 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Concert Pharmaceuticals is a late-stage clinical biopharmaceutical company that is developing CTP-543, a Janus Kinase 1 and Janus Kinase 2 inhibitor that Co. discovered through the application of its DCE Platform® (deuterated chemical entity platform). Co. is evaluating CTP-543 in a Phase 3 clinical program for the treatment of alopecia areata, a serious autoimmune dermatological condition. In addition to its wholly-owned development programs, Co. has entered into collaborative arrangements with companies to develop deuterium-modified versions of their marketed products.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
227,052 |
| Total Buy Value |
$0 |
$0 |
$0 |
$1,078,498 |
| Total People Bought |
0 |
0 |
0 |
3 |
| Total Buy Transactions |
0 |
0 |
0 |
3 |
| Total Shares Sold |
0 |
0 |
0 |
81,977 |
| Total Sell Value |
$0 |
$0 |
$0 |
$653,253 |
| Total People Sold |
0 |
0 |
0 |
6 |
| Total Sell Transactions |
0 |
0 |
0 |
14 |
| End Date |
2024-02-15 |
2023-11-14 |
2023-05-16 |
2022-05-16 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Wan Mark A |
10% Owner |
– – • |
2014-02-19 |
4 |
A |
$0.00 |
$0 |
I/I |
690,264 |
679,401 |
|
- |
|
| Qvt Fund V Lp |
10% Owner |
– – • |
2014-02-19 |
4 |
B |
$14.00 |
$4,200,000 |
I/I |
300,000 |
559,999 |
1.5 |
- |
|
| Qvt Fund V Lp |
10% Owner |
– – • |
2014-02-19 |
4 |
A |
$0.00 |
$0 |
I/I |
259,999 |
259,999 |
|
- |
|
| Glaxosmithkline Plc |
Former 10% Owner |
– – – |
2014-02-19 |
4 |
B |
$14.00 |
$490,000 |
I/I |
35,000 |
1,356,533 |
0.01 |
- |
|
| Glaxosmithkline Plc |
Former 10% Owner |
– – – |
2014-02-19 |
4 |
A |
$0.00 |
$0 |
I/I |
1,321,533 |
1,321,533 |
|
- |
|
| Tvm Life Science Ventures Vi Lp |
10% Owner |
– – • |
2014-02-19 |
4 |
B |
$14.00 |
$317,982 |
I/I |
22,713 |
378,703 |
1.5 |
- |
|
| Tvm Life Science Ventures Vi Lp |
10% Owner |
– – • |
2014-02-19 |
4 |
B |
$14.00 |
$928,018 |
D/D |
66,287 |
1,104,969 |
2.45 |
- |
|
| Tvm Life Science Ventures Vi Lp |
10% Owner |
– – • |
2014-02-19 |
4 |
A |
$0.00 |
$0 |
I/I |
342,437 |
355,990 |
|
- |
|
| Tvm Life Science Ventures Vi Lp |
10% Owner |
– – • |
2014-02-19 |
4 |
A |
$0.00 |
$0 |
D/D |
999,138 |
1,038,682 |
|
- |
|
| Hutt Peter Barton |
Director |
– • – |
2014-02-19 |
4 |
A |
$0.00 |
$0 |
D/D |
4,424 |
4,424 |
|
- |
|
| Tung Roger D |
Chief Executive Officer |
• • • |
2014-02-19 |
4 |
A |
$0.00 |
$0 |
I/I |
13,274 |
13,274 |
|
- |
|
| Tung Roger D |
Chief Executive Officer |
• • • |
2014-02-19 |
4 |
A |
$0.00 |
$0 |
D/D |
17,699 |
401,522 |
|
- |
|
| Kania Edwin M Jr |
10% Owner |
– – • |
2014-02-19 |
4 |
A |
$0.00 |
$0 |
D/D |
623,982 |
656,490 |
|
- |
|
| Aldrich Richard |
Director |
– • • |
2014-02-19 |
4 |
A |
$0.00 |
$0 |
I/I |
61,946 |
61,946 |
|
- |
|
| Greylock Xii-A Limited Partnership |
10% Owner |
– – • |
2014-02-19 |
4 |
A |
$0.00 |
$0 |
I/I |
672,565 |
67,256 |
|
- |
|
| Wan Mark A |
10% Owner |
– – • |
2014-02-12 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
25,663 |
|
- |
|
| Tvm Life Science Ventures Vi Lp |
10% Owner |
– – • |
2014-02-12 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
13,553 |
|
- |
|
| Tvm Life Science Ventures Vi Lp |
10% Owner |
– – • |
2014-02-12 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
39,544 |
|
- |
|
| Kaneko Yasunori |
10% Owner |
– – • |
2014-02-12 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
32,372 |
|
- |
|
| Jaeger Wilfred E |
Director |
– • • |
2014-02-12 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
25,663 |
|
- |
|
| Freund John Gordon |
Director |
– • • |
2014-02-12 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
32,372 |
|
- |
|
| Aldrich Richard |
Director |
– • • |
2014-02-12 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
102,417 |
|
- |
|
| Aldrich Richard |
Director |
– • • |
2014-02-12 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
286,963 |
|
- |
|
| Kania Edwin M Jr |
10% Owner |
– – • |
2014-02-12 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
32,508 |
|
- |
|
| Brookside Capital Partners Fund Lp |
10% Owner |
– – • |
2014-02-12 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
32,789 |
|
- |
|
279 Records found
|
|
Page 11 of 12 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
